Meng Lei

546 total citations
26 papers, 446 citations indexed

About

Meng Lei is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Meng Lei has authored 26 papers receiving a total of 446 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 16 papers in Oncology and 5 papers in Hematology. Recurrent topics in Meng Lei's work include Ubiquitin and proteasome pathways (16 papers), Peptidase Inhibition and Analysis (12 papers) and Multiple Myeloma Research and Treatments (5 papers). Meng Lei is often cited by papers focused on Ubiquitin and proteasome pathways (16 papers), Peptidase Inhibition and Analysis (12 papers) and Multiple Myeloma Research and Treatments (5 papers). Meng Lei collaborates with scholars based in China, United States and Taiwan. Meng Lei's co-authors include Yongqiang Zhu, Xiao Du, Xueyuan Wang, Yanru Qin, Haoyang Zhang, Fengyi Zhao, Mengtao Ma, Mengyi Zhou, Fuliang Cao and Zhaogang Liu and has published in prestigious journals such as Journal of Medicinal Chemistry, Carbohydrate Polymers and RSC Advances.

In The Last Decade

Meng Lei

26 papers receiving 439 citations

Peers

Countries citing papers authored by Meng Lei

Since Specialization

Citations

This map shows the geographic impact of Meng Lei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meng Lei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meng Lei more than expected).

Fields of papers citing papers by Meng Lei

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Meng Lei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meng Lei. The network helps show where Meng Lei may publish in the future.

Co-authorship network of co-authors of Meng Lei

This figure shows the co-authorship network connecting the top 25 collaborators of Meng Lei. A scholar is included among the top collaborators of Meng Lei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Meng Lei. Meng Lei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Synergistic effects of photodynamic therapy and chemotherapy: Activating the intrinsic/extrinsic apoptotic pathway of anoikis for triple-negative breast cancer treatment 2024 ·Biomaterials Advances ·Tianyu Zhang, Xueyuan Wang, (unknown), Meng Lei, (unknown), (unknown), Yuting Li, (unknown), Liefeng Zhang, Yongqiang Zhu	10
2	Discovery of SZJK-0421: A Novel Potent, Low Toxicity, Selective Second Generation of CRM1 Inhibitor for the Treatment of Both Hematological and Solid Tumors 2024 ·Journal of Medicinal Chemistry ·(unknown), Yanru Qin, D. Shao, Qinghua Chen, Yupeng Pan, Meng Lei, Raymond Wu, X. Ye, (unknown), Yongqiang Zhu	1
3	KPT‐330 and Y219 exert a synergistic antitumor effect in triple‐negative breast cancer through inhibiting NF‐κB signaling 2023 ·FEBS Open Bio ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Hui Zhou, Jia Wang, (unknown), Yin Zhang, Meng Lei, Yongqiang Zhu	3
4	Design and discovery of novel dipeptide boronic acid ester proteasome inhibitors, an oral slowly-released prodrug for the treatment of multiple myeloma 2023 ·European Journal of Medicinal Chemistry ·(unknown), Wen Zhang, (unknown), (unknown), (unknown), Hailong Liu, Meng Lei, Yongqiang Zhu	7
5	Discovery of a new class of valosine containing protein (VCP/P97) inhibitors for the treatment of colorectal cancer 2022 ·Bioorganic & Medicinal Chemistry ·(unknown), (unknown), (unknown), (unknown), Meng Lei, Yongqiang Zhu	6
6	Preclinical Pharmacokinetics, Tissue Distribution and in vitro Metabolism of FHND6091, a Novel Oral Proteasome Inhibitor 2022 ·Drug Design Development and Therapy ·Xu Yang, (unknown), Lin Yang, (unknown), Jia Wang, (unknown), Hui Zhou, (unknown), Meng Lei, Yongqiang Zhu	4
7	Discovery of novel tripeptide propylene oxide proteasome inhibitors for the treatment of multiple myeloma 2021 ·Bioorganic & Medicinal Chemistry ·Wen Zhang, (unknown), Haoyang Zhang, (unknown), Yang Lin, (unknown), Jia Wang, Hailong Liu, Yang Xu, Meng Lei, Yongqiang Zhu	2
8	Anti-tumor activity of a novel proteasome inhibitor D395 against multiple myeloma and its lower cardiotoxicity compared with carfilzomib 2021 ·Cell Death and Disease ·(unknown), Chao Wu, Meng Lei, Qing Yan, Haoyang Zhang, Lina Zhang, (unknown), Ye Yang, Jianyong Li, Yongqiang Zhu, Lijuan Chen	5
9	Development of oral curcumin based on pH-responsive transmembrane peptide-cyclodextrin derivative nanoparticles for hepatoma 2021 ·Carbohydrate Polymers ·(unknown), Yin Zhang, Meng Lei, Yanru Qin, Zhongjie Wang, (unknown), Liefeng Zhang, Yongqiang Zhu	34
10	<i>In vitro</i> and <i>in vivo</i> efficacy of the novel oral proteasome inhibitor NNU546 in multiple myeloma 2020 ·Aging ·Hui Zhou, Meng Lei, Wang Wang, Mengjie Guo, Jia Wang, Haoyang Zhang, Qiao Li, (unknown), Zhaogang Liu, Lijuan Chen, (unknown), (unknown), Chenxi Gu, Bing Zhao, Evgeny Izumchenko, Ye Yang, Yongqiang Zhu	4
11	Preparation and biological evaluation of soluble tetrapeptide epoxyketone proteasome inhibitors 2019 ·Bioorganic & Medicinal Chemistry ·Meng Lei, Haoyang Zhang, (unknown), Xiao Du, Hui Zhou, Jia Wang, (unknown), (unknown), (unknown), Zhaogang Liu, Jian Shen, Yongqiang Zhu	6
12	Dual-functionalized liposome by co-delivery of paclitaxel with sorafenib for synergistic antitumor efficacy and reversion of multidrug resistance 2019 ·Drug Delivery ·Meng Lei, (unknown), (unknown), Xueyuan Wang, (unknown), Yongqiang Zhu, Xiao Du	63
13	High anticancer potency on tumor cells of dehydroabietylamine Schiff-base derivatives and a copper(II) complex 2018 ·European Journal of Medicinal Chemistry ·Fengyi Zhao, Weifan Wang, Wen Lu, Li Xu, Shilong Yang, Xu‐Min Cai, Mengyi Zhou, Meng Lei, Mengtao Ma, Haijun Xu, Fuliang Cao	68
14	Discovery of a new class of valosine containing protein (VCP/P97) inhibitors for the treatment of non-small cell lung cancer 2018 ·Bioorganic & Medicinal Chemistry ·(unknown), (unknown), Hui Zhou, (unknown), (unknown), Yanru Qin, Zhaogang Liu, Jia Wang, Haoyang Zhang, Meng Lei, Jia Liu, (unknown), Yongqiang Zhu	13
15	Tumor associated macrophages and angiogenesis dual-recognizable nanoparticles for enhanced cancer chemotherapy 2018 ·Nanomedicine Nanotechnology Biology and Medicine ·Duo Cao, Lin Liang, Yixin Xu, Ji Sun, Meng Lei, Man Wang, Yahui Wei, Zhenliang Sun	10
16	Design, synthesis, in vitro and in vivo evaluation, and structure-activity relationship (SAR) discussion of novel dipeptidyl boronic acid proteasome inhibitors as orally available anti-cancer agents for the treatment of multiple myeloma and mechanism studies 2018 ·Bioorganic & Medicinal Chemistry ·Meng Lei, (unknown), (unknown), Hui Zhou, Jia Wang, (unknown), (unknown), Shihe Hu, (unknown), Yongqiang Zhu	8
17	Design, synthesis, SAR discussion, in vitro and in vivo evaluation of novel selective EGFR modulator to inhibit L858R/T790M double mutants 2017 ·European Journal of Medicinal Chemistry ·Haoyang Zhang, (unknown), Chao Feng, Zhaogang Liu, (unknown), Xueyuan Wang, Meng Lei, Hao Cheng, (unknown), (unknown), Jia Wang, (unknown), Jin Tao, Shanshan Chen, Shihe Hu, Yongqiang Zhu	36
18	Design, synthesis and docking studies of novel dipeptidyl boronic acid proteasome inhibitors constructed from αα- and αβ-amino acids 2016 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Meng Lei, (unknown), (unknown), Jia Wang, Shanshan Chen, Yongqiang Zhu, Shihe Hu, (unknown), Cheng Jiang	10
19	3D-QSAR-aided design, synthesis, in vitro and in vivo evaluation of dipeptidyl boronic acid proteasome inhibitors and mechanism studies 2016 ·Bioorganic & Medicinal Chemistry ·Meng Lei, (unknown), Cheng Wang, Hailing Li, (unknown), Jia Wang, (unknown), Shanshan Chen, Shihe Hu, Yongqiang Zhu	11
20	3D-QSAR studies of boron-containing dipeptides as proteasome inhibitors with CoMFA and CoMSIA methods 2008 ·European Journal of Medicinal Chemistry ·Yongqiang Zhu, Meng Lei, Aijun Lu, (unknown), (unknown), Qingzhi Gao	32

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact